Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab in Previously Untreated Multiple Myeloma
NCT05828511Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2023
- Primary completion
- Nov 2035
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Started Dec 2023; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05828511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828511.